Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiology/Diagnostic ImagingBlue Cross Blue Shield KS PET Coverage Update | Op…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - KansasPolicy N/A

    PET Scanning - Oncologic Applications (Bone and Sarcoma)

    Customize your policy alerts

    Sign up for all blue cross blue shield - kansas policy alerts

    Know when blue cross blue shield - kansas releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy describes when 18F-FDG PET or PET/CT is considered medically necessary, experimental/investigational, or otherwise for diagnosis, staging, restaging, and surveillance of bone and soft tissue sarcomas for Blue Cross and Blue Shield of Kansas members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET Scanning - Oncologic Applications (Bone and Sarcoma)
    Policy CodePolicy N/A
    Change TypeStandalone policycontent updates
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify member benefits and any applicable prior authorization requirements with Blue Cross and Blue Shield of Kansas before scheduling.
    SourceLink
    POLICY UPDATE CHANGES

    Oncologic Applications for Bone and Sarcoma was separated into its own medical policy; medical policy language was unchanged.

    FDG-PET or FDG-PET/CT were added to Sections A1, A2, B1 and B2.

    Tyrosine Kinase Inhibitors (TKI) were added to Section B1.

    Imatinib was removed from policy language where previously referenced.

    A duplicate statement (Statement C) was removed as it duplicated B1.

    Description and Policy sections were updated and the Description section was updated again on 01-13-2026.

    2sarcoma categories with coverage statements
    18F-FDGprimary radiotracer discussed
    4PET oncology applications defined
    4oncology PET use categories defined
    lowreduced sensitivity for lung mets

    Coverage Criteria for FDG-PET / FDG-PET/CT in Bone and Soft Tissue Sarcoma

    inv-01: Bone sarcoma — Medically necessary

    Covered when ALL of the following are met for bone sarcoma:

    Bone sarcoma - Ewing sarcoma and osteosarcoma: FDG-PET or FDG-PET/CT may be considered medically necessary in the staging or restaging of Ewing sarcoma and osteosarcoma.

    inv-02: Bone sarcoma — Experimental / investigational

    Bone sarcoma - chondrosarcoma: FDG-PET or FDG-PET/CT is considered experimental/investigational for staging of chondrosarcoma.

    inv-03: Soft tissue sarcoma — Medically necessary (GIST treatment response)

    Covered when ALL of the following are met for soft tissue sarcoma:

    GIST therapy response: FDG-PET or FDG-PET/CT is considered medically necessary for evaluating response to tyrosine kinase inhibitors (TKI) and other treatments for gastrointestinal stromal tumors (GIST).

    inv-04: Soft tissue sarcoma — Experimental / investigational (other applications)

    Soft tissue sarcoma - other indications: FDG-PET or FDG-PET/CT is considered experimental/investigational for evaluation of soft tissue sarcoma including: (a) distinguishing between benign lesions and malignant soft tissue sarcoma; (b) distinguishing between low-grade and high-grade soft tissue sarcoma; (c) detecting locoregional recurrence; (d) detecting distant metastasis.

    inv-05: Bone sarcoma: Diagnostic/staging/restaging

    Covered when evidence supports diagnostic/staging/restaging utility:

    Bone sarcoma - diagnosis/staging/restaging: FDG-PET and FDG-PET/CT are supported for diagnosis, staging, and restaging of bone sarcoma based on systematic reviews and meta-analyses showing high pooled sensitivity and specificity; consider adjunct chest CT for lung metastasis evaluation due to reduced sensitivity of PET for pulmonary lesions.

    inv-06: Soft tissue sarcoma: Response assessment and selective staging uses

    Covered when evidence supports specific uses in soft tissue sarcoma and related tumors:

    Soft tissue sarcoma - response assessment and selective staging: FDG-PET/CT may be useful for rapid assessment of response to targeted therapies (eg, TKI therapy for GIST) and for selective staging/prognostication per NCCN in certain soft tissue sarcoma subtypes; overall evidence is insufficient for routine diagnostic/staging use in soft tissue sarcoma and PET has limited accuracy distinguishing low-grade tumors from benign lesions.

    Useful when rapid readout of TKI activity is necessary (eg, 2–4 weeks) and in selected NCCN-supported scenarios.

    inv-07: Defined PET clinical applications

    Policy discusses PET use in the following oncology applications and ties medical necessity to those contexts

    Defined PET clinical applications: Diagnosis: PET as part of testing to establish whether a patient has cancer; Staging: use of PET to determine extent at diagnosis before treatment; Restaging: (a) evaluation when recurrence is suspected by signs/symptoms, (b) determining extent after completion of treatment; Surveillance: imaging in asymptomatic patients ≥6 months after treatment (≥12 months for lymphoma).

    These definitions frame coverage decisions in the policy.

    FDG-PET and FDG-PET/CT are designated experimental/investigational for multiple soft tissue sarcoma applications. Specifically, PET is not considered medically necessary for: (a) distinguishing benign from malignant soft tissue lesions; (b) distinguishing low-grade from high-grade soft tissue sarcomas; (c) detecting locoregional recurrence; and (d) detecting distant metastasis.

    Use of FDG-PET and FDG-PET/CT for routine surveillance of bone sarcoma or soft tissue sarcoma is not supported by the evidence and therefore is considered not medically necessary. Surveillance in this policy refers to imaging in asymptomatic patients performed ≥6 months after treatment to detect recurrence.

    The inclusion or exclusion of procedure, diagnosis, or device codes in this policy document does not, by itself, determine member coverage or provider reimbursement. Coverage applicability is determined by the member's contract benefits in effect at the time of service and any applicable prior authorization rules.

    Staging of chondrosarcoma is explicitly labeled experimental/investigational in this policy. In addition, many evaluative applications for soft tissue sarcoma (as listed in the policy) are also considered experimental/investigational and therefore not medically necessary per the policy statements.

    FDG-PET/FDG-PET-CT is not supported for routine surveillance of either bone sarcoma or soft tissue sarcoma based on available evidence and is therefore not considered medically necessary for surveillance indications.

    Procedure and radiopharmaceutical codes referenced in this policy are considered medically necessary only if the imaging study is performed in accordance with the applicable Policy section. Documentation of medical necessity per the policy is required for coverage consideration.

    Indications Considered Medically Necessary

    inv-39: Staging/restaging of Ewing sarcoma and osteosarcoma

    Staging/restaging of Ewing sarcoma and osteosarcoma: FDG-PET or PET/CT for staging or restaging is medically necessary for Ewing sarcoma and osteosarcoma.

    inv-40: Therapy response assessment in GIST

    Therapy response assessment in GIST: FDG-PET or PET/CT is medically necessary for evaluating response to TKI and other treatments in gastrointestinal stromal tumors; PET/CT may provide an early indication of TKI activity (eg, 2–4 weeks) per NCCN and systematic reviews.

    Baseline PET/CT is recommended if PET/CT will be used during follow-up in unresectable, recurrent, or metastatic disease.

    inv-41: Other soft tissue sarcoma evaluations — not covered (experimental/investigational)

    Relevant Procedure and Radiopharmaceutical Codes

    Radiotracermixed
    18F-FDGFluorine 18 fluorodeoxyglucose radiotracer
    Included PET/PET-CT radiology codesCPT/HCPCS
    78608Brain imaging, positron emission tomography (PET); metabolic evaluation
    78609Brain imaging, positron emission tomography (PET); perfusion evaluation
    78811Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck)
    78812Positron emission tomography (PET) imaging; skull base to mid-thigh
    78813Positron emission tomography (PET) imaging; whole body
    78814Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; limited area (e.g. chest, head/neck)
    78815Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; skull base to mid-thigh
    78816Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; whole body
    A9552Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries
    A9597Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
    1–10 of 12
    1/2
    Listed PET and radiopharmaceutical codesCPT | HCPCS
    78608Brain imaging, positron emission tomography (PET); metabolic evaluation
    78609Brain imaging, positron emission tomography (PET); perfusion evaluation
    78811Positron emission tomography (PET) imaging; limited area (e.g. Chest, head/neck)
    78812Positron emission tomography (PET) imaging; skull base to mid-thigh
    78813Positron emission tomography (PET) imaging; whole body
    78814Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; limited area (e.g. chest, head/neck)
    78815Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; skull base to mid-thigh
    78816Tumor imaging, positron emission tomography (PET) with concurrently acquired CT; whole body
    A9552Fluorodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 millicuries
    A9597Positron emission tomography radiopharmaceutical, diagnostic, for tumor identification, not otherwise classified
    1–10 of 12
    1/2

    Provider Actions, Documentation, and Billing Guidance

    Prior Authorization

    Prior Authorization / Code Applicability

    Verify member benefits and obtain prior authorization as required by the member's contract before scheduling PET/PET‑CT. Coverage and precertification rules vary by plan; contact Blue Cross and Blue Shield of Kansas Customer Service to confirm eligibility and any specific prior authorization requirements.

    • Affected codes include PET imaging CPT codes (e.g., 78811-78816, 78608-78609), PET radiopharmaceutical HCPCS (A9552, A9597, A9598), and G0235. Prior authorization may be required for these services per the member's plan.
    Documentation Required

    Medical Necessity Tied to Policy

    FDG‑PET or FDG‑PET/CT procedures are covered only when performed in accordance with the Policy section criteria for bone sarcoma and soft tissue sarcoma (e.g., staging/restaging for Ewing sarcoma and osteosarcoma; evaluation of response to TKI in GIST). Procedures performed for indications that do not meet the policy medical‑necessity criteria may be denied.

    Definitions

    Surveillance definition
    DefinitionSurveillance refers to imaging in asymptomatic patients completed 6 months or more after completion of treatment (≥12 months for lymphoma).
    PurposeDetect recurrence in patients without objective signs or symptoms of disease recurrence.
    TimingPerformed at least 6 months after treatment completion; lymphoma surveillance uses a threshold of ≥12 months.
    Restaging definition
    DefinitionRestaging refers to imaging after treatment in two situations: (a) evaluation when disease recurrence is suspected based on signs and/or symptoms; (b) determining the extent of malignancy after completion of a full course of treatment.
    IndicationsSymptomatic patients with suspected recurrence; assessment of residual or recurrent disease after treatment completion.

    Background

    Positron emission tomography (PET) is a nuclear imaging technique that uses positron-emitting radiotracers (most commonly 18F-FDG) to image metabolic activity. In oncology, FDG-PET and FDG-PET/CT can aid in diagnosis, staging, restaging, surveillance, and assessment of treatment response, although the clinical utility varies by tumor type and specific indication.

    Prior Authorization and Authorization Notes

    Prior Authorization

    Verify benefits and prior authorization with BCBSKS

    Verify member benefits and any applicable prior authorization requirements with Blue Cross and Blue Shield of Kansas before scheduling PET or PET/CT; member contract language and state/federal mandates take precedence.

    Prior Authorization

    Obtain prior authorization for PET/CT when indication is outside supported uses

    When a PET/CT is requested for surveillance or other uses outside the policy’s supported indications, ensure prior authorization is obtained because PET/CT is required in those circumstances per payer rules.

    Prior Authorization

    Ensure procedure meets policy criteria and member contract for coverage

    Coverage for PET and PET/CT requires that the requested procedure meet the policy’s medical necessity criteria and the member’s contract benefits; prior authorization may apply per payer rules.

    Not Covered / Experimental or Investigational Indications

    The following uses of FDG-PET are not covered under this policy: staging of chondrosarcoma; use to distinguish benign versus malignant soft tissue lesions; use to differentiate tumor grade (low vs high) in soft tissue sarcomas; and many other evaluative soft tissue sarcoma applications cited as experimental/investigational. Evidence summarized in systematic reviews found low diagnostic accuracy for many soft tissue sarcoma indications, supporting these non-coverage determinations.

    Policy Summary
    PayerBlue Cross Blue Shield - Kansas
    PolicyPET Scanning - Oncologic Applications (Bone and Sarcoma)
    Policy CodePolicy N/A
    Change TypeStandalone policycontent updates
    Effective DateN/A
    Next Review DateN/A
    Key ActionVerify member benefits and any applicable prior authorization requirements with Blue Cross and Blue Shield of Kansas before scheduling.
    SourceLink
    On This Page
    Coverage Criteria for FDG-PET / FDG-PET/CT in Bone and Soft Tissue SarcomaIndications Considered Medically NecessaryRelevant Procedure and Radiopharmaceutical CodesProvider Actions, Documentation, and Billing GuidanceDefinitionsBackgroundPrior Authorization and Authorization NotesNot Covered / Experimental or Investigational Indications
    Other soft tissue sarcoma evaluations - not covered: FDG-PET or PET/CT for distinguishing benign vs malignant soft tissue lesions, grade differentiation, detecting locoregional recurrence, or detecting distant metastasis in soft tissue sarcoma is considered experimental/investigational and not covered.

    inv-42: Suspected primary bone tumor or diagnostic workup per ACR/NCCN

    Suspected primary bone tumor or diagnostic workup per ACR/NCCN: FDG-PET/CT of the whole body is usually appropriate for suspected primary bone tumors with indeterminate or aggressive radiographic appearance (ACR 2024); NCCN also considers PET/CT for diagnostic workup of chordoma, Ewing sarcoma, and osteosarcoma.

    inv-43: Restaging and detecting metastases in bone sarcoma

    Restaging and detecting metastases in bone sarcoma: FDG-PET and FDG-PET/CT demonstrate high sensitivity and specificity for detecting recurrence and distant metastases in bone sarcoma (pooled sensitivities ~90%+), though PET has reduced sensitivity for lung metastases; consider complementary chest CT when evaluating for pulmonary metastases.

    inv-44: Rapid response assessment to TKI therapy (GIST)

    Rapid response assessment to TKI therapy (GIST): FDG-PET/CT may be used to monitor response to TKIs and can provide an early readout of activity (eg, within 2–4 weeks), enabling adaptation of therapy when rapid assessment is required.

    Useful in unresectable, recurrent, or metastatic disease where baseline PET/CT will be used during follow-up.

    inv-45: FDG-PET / FDG-PET/CT for diagnostic, staging, restaging, and surveillance in bone and sarcoma

    FDG-PET / FDG-PET/CT use for bone and sarcoma: FDG-PET or FDG-PET/CT is included in this policy for diagnostic, staging, and restaging indications in bone sarcoma and for selected uses in soft tissue sarcoma (notably therapy response in GIST); surveillance imaging for bone or soft tissue sarcoma is not supported by the evidence.

    Inclusion of codes does not guarantee coverage; member contract and medical necessity per policy apply.

    • Medical necessity for listed PET CPT/HCPCS codes is contingent on meeting the specific clinical criteria in the Policy section.
    • Requests for PET for surveillance of bone or soft tissue sarcoma (asymptomatic follow-up) are not supported by the evidence and may be denied (see policy guidance).
    Billing Rule

    Coding and Medical Necessity Documentation

    Document the clinical rationale clearly in the request and medical record. Include the indication (diagnosis and clinical application), sarcoma type (e.g., Ewing sarcoma, osteosarcoma, GIST), relevant signs/symptoms, prior treatments, and how the PET result will affect management. For billing, document the performed procedure, diagnosis code(s), and radiopharmaceutical HCPCS code.

    • Include sarcoma subtype, purpose of imaging (staging, restaging, response assessment), and prior imaging/treatment history in documentation.
    • Record the exact CPT/HCPCS procedure code (e.g., 78812, 78815), radiopharmaceutical code (e.g., A9552), and ICD‑10 diagnosis codes on the claim.
    • Indicate if the PET is being used to assess early response to TKI therapy (e.g., imatinib) for GIST, and provide timing relative to therapy (baseline, 2–4 weeks after initiation when applicable per NCCN).
    Note

    Use in Therapy Response Assessment

    Use FDG‑PET/CT for therapy response assessment when supported by the policy and guidelines — for example, early assessment of response to tyrosine kinase inhibitor (TKI) therapy in gastrointestinal stromal tumors (GIST). Obtain a baseline PET/CT if PET will be used for follow‑up assessment.

    • NCCN guidance: FDG‑PET/CT may indicate TKI activity after 2–4 weeks of therapy; a baseline FDG‑PET/CT is recommended if using PET during follow‑up for unresectable, recurrent, or metastatic GIST.
    • Clearly state in documentation that PET is for response assessment to TKI (or other specified therapy) and provide dates of therapy initiation and prior imaging.
    Denial Risk

    Denial Triggers and Experimental/Investigational Indications

    Requests for indications considered experimental/investigational by this policy (e.g., staging of chondrosarcoma; many soft tissue sarcoma diagnostic applications) are at high risk for denial. Surveillance imaging in asymptomatic patients is generally not supported and may be denied.

    • Experimental/investigational examples: PET for staging chondrosarcoma; PET for distinguishing benign versus malignant soft tissue lesions, grading soft tissue sarcoma, detecting locoregional recurrence or distant metastasis for soft tissue sarcomas.
    • Surveillance: PET for routine asymptomatic surveillance after treatment for bone or soft tissue sarcoma is not supported by the evidence and may be denied.
    ScopeIncludes both targeted evaluation for suspected recurrence and comprehensive assessment of disease extent post-therapy.
    Clinically useful definition
    DefinitionClinically useful: a test whose results inform management decisions that improve net health outcome, e.g., enabling correct or more effective therapy or avoiding unnecessary treatments or tests.
    Evidence expectationStudies should demonstrate how imaging results impacted treatment decisions and overall patient management to ascertain clinical usefulness.
    Outcome focusClinical utility ideally reflects long-term patient status and improvement in net health outcomes.
    Direct evidence vs chain of evidence
    Direct evidenceStudies that compare health outcomes for individuals managed with and without the test (preferably randomized controlled trials).
    Chain of evidence (indirect)Relies on clinical validity (test performance: sensitivity/specificity) to infer clinical utility when direct outcome studies are limited.
    ImplicationIf test performance evidence is insufficient, no inferences about clinical utility can be made; indirect evidence can support utility when validity is established.
    Surveillance (repeat) definition
    DefinitionSurveillance: use of imaging in asymptomatic patients (without objective signs or symptoms of recurrent disease) completed 6 months or more after treatment (≥12 months for lymphoma).
    Contrast with restagingSurveillance is performed in asymptomatic patients, whereas restaging is performed when recurrence is suspected or to assess extent after treatment completion.
    Policy relevanceSurveillance definitions are used to frame coverage decisions; routine surveillance with FDG-PET/CT for bone or soft tissue sarcoma is not supported by the evidence per policy.
    Staging definition
    DefinitionStaging refers to use of PET to determine the stage (extent) of the cancer at the time of diagnosis before any treatment is given (initial staging).
    PurposeDetermine whether cancer is localized and to guide initial treatment planning.
    Alternate termAlso referred to as initial staging in the policy guidelines.
    Restaging (repeat) definition
    DefinitionRestaging refers to imaging after treatment either when recurrence is suspected based on signs/symptoms or to determine extent after completion of treatment.
    Subcategories(a) Evaluation for suspected recurrence; (b) Assessment of extent following completion of a full course of therapy.
    Use caseApplied when symptoms suggest recurrence or for post-treatment disease extent evaluation to inform further management.
    Diagnosis definition
    DefinitionDiagnosis refers to use of PET as part of the testing used in establishing whether a patient has cancer.
    RolePET is one component of diagnostic evaluation and may be used alongside other imaging or tests to establish presence of malignancy.
    Policy noteDiagnosis is one of four defined oncology applications (diagnosis, staging, restaging, surveillance) used to determine medical necessity in the policy.